FindMyKOL
Clinical trialNCT02197065CompletedPhase 2Interventional

Pilot Study of Atorvastatin for Orthopedic Surgery Patients

NCT02197065 is a phase 2 interventional trial sponsored by Hospital for Special Surgery, New York. As of 18 Nov 2026, it is completed. It studies Atorvastatin and Placebo in Hip Fracture, Inflammation and 1 more condition. The registry lists an enrollment of 20 participants at 2 sites in 1 country. The registry lists a start date of 30 Sept 2014 and a primary completion date of 31 Jul 2016. One of its registered investigators has a FindMyKOL profile.

SponsorHospital for Special Surgery, New YorkEnrollment20Hip FractureInflammationMyocardial Ischemia
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02197065
FieldValue
Registry IDNCT02197065
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorHospital for Special Surgery, New York
Enrollment20
Registered sites2
Countries1
ConditionsHip Fracture, Inflammation and Myocardial Ischemia
DrugsAtorvastatin and Placebo
Start30 Sept 2014
Primary completion31 Jul 2016
Study completion31 Jan 2017
Last update posted2 Jul 2017

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Up to 35% of hip fracture patients have been shown to experience heart injury after surgery, and as many as 10% have a heart attack or die in the three months after surgery. Hip and knee arthroplasty patients are also at risk of cardiovascular complications. Patients who have these complications have higher levels of inflammation postoperatively. Statins (such as atorvastatin/Lipitor) lower cholesterol and also lessen inflammation. Both of these effects are important in preventing heart attacks. Statins have been shown to reduce the risk of heart attacks in non-surgical patients, and to protect from heart attacks in patients having heart surgery. Whether statins can prevent heart attacks in orthopedic patients is not known. In this pilot study the investigators will treat 30 orthopedic surgery patients (hip fracture, hip or knee arthroplasty) with either atorvastatin or placebo (a capsule with no study drug). Patients will start the study drug prior to surgery and take it for 45 days after surgery. Neither the doctors nor the patients will know whether they are taking atorvastatin or placebo. The investigators will look for evidence of inflammation and heart injury after surgery. The investigators hypothesize that atorvastatin will lessen the degree of postoperative inflammation found in these patients. In this study, the investigators will use a very sensitive test of heart injury that can detect problems even when patients have no symptoms. The investigators hypothesize that this test will demonstrate silent heart injury in over 50% of the hip fracture patients and over 30% of arthroplasty patients in our study. The results of this trial will help us to develop a larger study in 1000 hip fracture and joint replacement patients to determine whether atorvastatin protects orthopedic surgery patients from heart injury and other complications of surgery.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New York, United States2 sites
  • Hospital for Special Surgery

    New York

  • New York Presbyterian Hospital (cornell)

    New York

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 2 sitesNY2MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT02197065

Each answer restates registry values shown on this page.

What is NCT02197065?

NCT02197065 is a phase 2 interventional trial sponsored by Hospital for Special Surgery, New York. It studies Atorvastatin and Placebo in Hip Fracture, Inflammation and 1 more condition.

Who leads NCT02197065?

The registry names Anne R Bass, MD (principal investigator, Hospital for Special Surgery, New York) as the overall official.

Where does NCT02197065 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT02197065 study?

The registered drug and biological interventions are Atorvastatin and Placebo.

When did NCT02197065 end?

The registry lists a primary completion date of 31 Jul 2016 and a study completion date of 31 Jan 2017. The sponsor last updated the record on 2 Jul 2017.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.